Q3 EPS Estimates for Fractyl Health Boosted by HC Wainwright

Posted by George Bondi on Aug 13th, 2026

Fractyl Health, Inc. (NASDAQ:GUTS – Free Report) – Analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Fractyl Health in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Fractyl Health’s Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.36) EPS.

Fractyl Health (NASDAQ:GUTS – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02.

A number of other equities analysts have also recently issued reports on the company. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings cut Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Finally, Craig Hallum initiated coverage on Fractyl Health in a research note on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.12.

Read Our Latest Report on Fractyl Health

Fractyl Health Stock Down 0.8%

Shares of GUTS opened at $0.70 on Thursday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $2.44. The stock has a market capitalization of $110.79 million, a price-to-earnings ratio of -0.79 and a beta of 2.32. The stock has a fifty day moving average of $0.76 and a 200-day moving average of $0.68.

Hedge Funds Weigh In On Fractyl Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in Fractyl Health in the second quarter valued at approximately $31,000. Jump Financial LLC bought a new position in Fractyl Health during the 4th quarter worth approximately $57,000. Scientech Research LLC bought a new position in Fractyl Health during the 3rd quarter worth approximately $49,000. Prelude Capital Management LLC acquired a new position in shares of Fractyl Health in the 3rd quarter worth approximately $55,000. Finally, Commonwealth Equity Services LLC acquired a new position in shares of Fractyl Health in the 4th quarter worth approximately $85,000.

Insider Buying and Selling at Fractyl Health

In related news, Director William Bradley purchased 68,493 shares of Fractyl Health stock in a transaction on Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $49,999.89. Following the transaction, the director owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ian Sheffield purchased 35,000 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, with a total value of $25,550.00. Following the purchase, the director owned 35,000 shares of the company’s stock, valued at approximately $25,550. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 171,493 shares of company stock valued at $127,150. 8.52% of the stock is owned by corporate insiders.

About Fractyl Health

(Get Free Report)

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.